EC
Erez Chimovits (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in ADARx Pharmaceuticals, Inc. (ADRX). Across 2 priced purchase filings, the average 21-session return was -8.1% from execution and -4.0% from disclosure (delay-adjusted; derived). The largest single filing was $34.9M of BRVE (1,940,000 sh across 2 lots, as filed), executed Aug 7. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-8.1%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-4.0%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$36.0M
shares × price, as filed
Last traded
Sep 28
Filed Sep 30
Median ADV $46.2M across their filed names
Open performance→Volume by month
Buys $36.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
ADRXRecent filings
ADRXPURCHASE
ADARx Pharmaceuticals, Inc.
View filing →
$1.0M61,516 sh × $17.00
Exec Sep 28
Filed Sep 30 · 5:29 PM ET BRVEPURCHASE Braveheart Bio, Inc. View filing → $34.9M
1,940,000 sh across 2 lots
Exec Aug 7
Filed Aug 11 · 5:31 PM ET